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ABSTRACT 
Identification of PTEN Modifier Genes Using the Collaborative Cross Mouse Panel  
  
Rachel Thomas 
Department of Genetics 
Texas A&M University 
 
Research Advisor: Dr. David Threadgill 
Department of Genetics 
Texas A&M University 
 
 Inactivation or mutation of phosphatase and tensin homolog (PTEN), a tumor suppressor 
gene, is implicated in unregulated cell proliferation, leading to tumor growth and the 
development of cancer. Identification of modifier genes, genes that alter the phenotype of 
another gene, of PTEN and their role in altering PTEN activity could provide insights into 
relationship between PTEN and cancer. The purpose of this study was to identify PTEN modifier 
genes by quantitative trait loci (QTL) mapping. To do so, we crossed transgenic mice that 
overexpress PTEN (super-PTEN) to lines of the Collaborative Cross (CC), a mouse population 
modeling human genetic diversity. We evaluated body weight at weaning as a surrogate for 
PTEN activity because it has been previously reported that super-PTEN expression is associated 
with reduced weight at weaning. Difference in body weight at weaning of super-PTEN pups 
compared to wild-type littermates was used for QTL analysis to identify modifier genes of 
PTEN.  This approach has identified candidate genomic intervals harboring PTEN modifier 
genes. Further studies will identify candidate genes and confirm these genes as modifiers. A pilot 
study has been initiated to verify that the effect of PTEN on body weight is indicative of the 
effect of PTEN on cancer susceptibility.  
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NOMENCLATURE  
 
PTEN  Phosphatase and tensin homolog (Protein) 
PTEN/Pten Phosphotase and tensin homolog (gene and transcripts for human/mouse) 
CC  Collaborative Cross Panel 
QTL  Quantitative Trait Locus Mapping  
NCBI  National Center for Biotechnology Information 
gQTL    Genome Quantitative Trait Locus Mapping  
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CHAPTER I 
INTRODUCTION 
 
Cancer, a disease characterized by rapidly dividing, genetically abnormal cells, is 
responsible for a large number of deaths and poses a prevalent threat to human health ("Centers 
for Disease Control and Prevention," 2016). While the etiology underlying the development of 
cancer is not fully understood, it is known that inactivation of tumor suppressor genes is a crucial 
step in the development of tumors. Tumor suppressor genes are responsible for cell growth 
control; they code for negative regulatory proteins that regulate cell proliferation and prevent or 
slow the development of tumors. Therefore, when tumor suppressor genes are inactive, they are 
unable to regulate cell proliferation, contributing to the development of tumors (Cooper, 2000). 
Phosphatase and Tensin Homolog 
Phosphatase and tensin homolong (PTEN) is a tumor suppressor that works through 
negative regulation of the phosphoinositide 3-kinase (PI3K) pathway, which contributes to 
cellular proliferative signals (Figure 1). The PTEN tumor suppressor gene codes for a lipid 
phosphatase protein that dephosphorylates the 3 position of phosphatidylinositol-3,4,5-
triphosphate (PIP3), a second messenger molecule which permits continued cell growth and 
proliferation, converting it back to PIP2 and preventing the continuation of the signaling cascade. 
Inactivation of PTEN through deletion or mutation is involved in the production of tumors in 
multiple types of cancers including prostrate, breast, melanoma and some brain cancers (Garcia-
Cao et al., 2012).  
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Previous PTEN Studies 
Previous studies have made progress in elucidating the role of PTEN in cancer. Studies 
evaluating PTEN in Drosophila melanogaster revealed it influences cell size and number. 
Studies of PTEN overexpression in mice showed that Tg(Pten)GPpp mice (hereafter called 
Super-PTEN mice) are smaller in size and show reduced tumor progression. Results of these 
studies showed that even slight changes in Pten expression could have a profound impact on the 
resulting cancer phenotype in mice treated with a carcinogen (Garcia-Cao et al., 2012). 
Distinguishing and understanding genetic modifiers, genes that can alter PTEN activity, could 
provide information on the causes, susceptibility and prevention of cancer. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The PI3K-PTEN-AKT pathway. PTEN is 
a tumor suppressor gene that is involved in the 
P13K pathway. (Molinari, 2014) 
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Modifier Genes 
 Modifier genes alter the phenotypic expression of another gene. They can affect the 
dominance, modification, expressivity and/or penetrance of phenotypes. Modifier genes account 
for differences between the genotype of genetic diseases and their phenotypic expression 
(Nadeau, 2001). Identifying PTEN modifier genes and studying their role could provide 
information on the relationship between PTEN and cancer. 
Studying Modifier Genes with the Collaborative Cross  
  The Collaborative Cross (CC), a panel of inbred mouse strains that contains levels of 
genetic variation similar to that of humans, is a new resource in mammalian genetics that can be 
utilized to identify modifier genes. The CC was derived from five inbred laboratory strains and 
three inbred wild-derived strains that were crossed and inbred for 20 generations to create mouse 
models that more accurately represent human genetic diversity (Aylor et al., 2011). The CC 
panel allows the identification of the role of novel genetic factors. Genetic modifiers can be 
identified by breeding CC mice with Super-PTEN mice that overexpress PTEN, and then using 
association mapping to identify genomic intervals that contribute to a selected phenotype, 
providing higher resolution mapping than other available resources. The CC panel allows for 
easier identification of potential modifier gene candidates through QTL mapping. 
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Objectives 
 We hypothesized that modifier genes can alter PTEN activity. Studying modification of 
PTEN function will provide information on the relationship between PTEN and cancer. The 
objectives of this project are to determine if PTEN modifiers exist using the CC population and 
observe the effects of the modifiers on cancer in mice.  
 
 
 
 
 
 
 
 
Figure 2: The CC was derived from five 
inbred laboratory strains and three wild 
strains that were crossed and inbred for a 
subsequent 20 generations 
Figure 3: Breeding Scheme. Super-PTEN 
female mice were bred with male CC mice 
to produce offspring with various PTEN 
phenotypes. 
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CHAPTER II 
METHODS 
 
The purpose of this research project is to test whether PTEN modifier genes exist in mice 
and identify genomic regions harboring PTEN modifier genes.   
Identifying CC Strains with Modified PTEN Function 
The first part of the project involved breeding super-PTEN female mice with CC male 
mice of 33 CC strains (breeding scheme shown in Figure 3) and comparing the offspring with 
and without the PTEN transgene. Super-PTEN mice are distinguishable from their non-
transgenic littermates by their reduced body weight at weaning, which is confirmed by 
genotyping. Average weight reduction of PTEN mice compared to their wild type littermates is 
16%, but weight reduction can range from 0%-29% (Figure 4).  This difference in weight was 
used to identify CC strains that possibly have modified PTEN function. Ear punch tissue samples 
were collected upon weaning and used for genotyping the mice. 
 
 
 
 
Figure 4. Weight at Weaning Data. The 
distribution of the weaning-weight phenotype 
is shown across 40 different CC mouse 
strains, including 10 strains that show a 
reasonable standard deviation from the 
average and 5 strains that deviate further. 
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Quantitative Trait Locus (QTL) Mapping 
 The body weight at weaning for both super-PTEN and non-transgenic littermates was 
used as a surrogate phenotype for PTEN activity in quantitative trait locus (QTL) analyses to 
identify regions of the genome containing modifiers of PTEN activity. To control for differences 
across litters and strains, the weight at weaning phenotype was expressed as a proportion; the 
weight at weaning of male/female super-PTEN mice was compared to the weight at weaning of 
their wild type littermates.  
QTL mapping was performed using gQTL. The QTL analysis produces LOD plots of 
statistical association (Figure 5). The higher peaks on the LOD plot indicate loci with more 
significant association to the PTEN-dependent weight phenotype. Candidate genes can then be 
explored in genome databases, such as the National Center for Biotechnology Information 
(NCBI), to identify genes present within the regions of significance with the highest LOD scores. 
The identified genes are possible candidate modifiers of PTEN; further tests will determine their 
effect on PTEN activity and function. 
 
 Figure 5. LOD Plot. Association mapping 
through gQTL produces LOD plots that are 
used to identify candidate loci.  
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CHAPTER III 
RESULTS 
 
 QTL mapping identified genomic regions harboring possible candidate PTEN modifier 
genes.  
QTL Mapping Results  
 The body weight at weaning from both super-PTEN and non-transgenic littermates was 
used as a surrogate phenotype for PTEN activity in quantitative trait locus (QTL) analyses and 
regions of the genome containing modifiers of PTEN activity were identified. To control for 
differences between the sexes, two separate gQTL analysis were performed using male and 
female data.  
Male Mice  
 The gQTL analysis with data from the male mice identified a locus on chromosome 2, 
significant at a 90% level (P<.1) (Figure 6). This locus contains 8 genes, including Sfmbt2 
located within the interval of the most significant LOD score, indicating that the Sfmbt2 gene 
may have a significant association with the PTEN-dependent weight phenotype. Also present 
within the locus is Mir466, a gene encoding a microRNA known to regulate apoptosis (Druz et 
al., 2011), making this gene a promising candidate gene given the role of PTEN in apoptosis. 
This is potentially relevant to PTEN activity because inactivation or mutation of PTEN is 
implicated in inhibited apoptosis, continued cell proliferation and the development of tumors. 
Other candidate genes identified in the male mice include Itih5, Itih2, Kin, ATp5c1, Taf3, Gata3 
and Celf2.  
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 An allele effects figure generated through gQTL showed that the observed phenotypic 
effect at the identified locus is derived from three parental mouse strains, the CAST/EiJ, 
PWK/PhJ and WSB/EiJ (Figure 7). The colors on the graph indicate the genomic segments from 
different parental strains that are causing the association. 
  
Female Mice Results  
 The gQTL analyses on female mice (both super-PTEN and their non-transgenic 
littermates) showed significant peaks on chromosomes 3(p <.1 )  and 12(p<.1) (figure 8). The 
  
 Figure 6. LOD Plot for Male Mice. Depicts the association between the surrogate phenotype 
 (weight at weaning) and areas of the genome. The green and blue dashed lines indicate the      
significant thresholds at p=8.7 and p=9.0, respectively.  
 
Figure 7. Allele Effects in Male Mice. Some mice strains contribute more than others to the 
observed phenotypic effect.   
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locus on chromosome 3, the region within the peak (+/-1 LOD) contains 10 candidate genes, 
while the genomic region identified by a peak in chromosome 12 contains 8 candidate genes, 
including the transcription factor, Gtf2a1, which may be involved in regulating PTEN 
transcription (Huang et al., 2009).   
  
 
 
 
 
 
 
 
 
 Additional weight at weaning data collection will improve the resolution of the LOD 
plots. With a higher resolution provided by the additional data, we hope to uncover additional 
significant loci associated with PTEN activity modification. Our current efforts are to confirm 
the identity of candidate genes from these loci as PTEN modifier genes and to validate their roles 
in the PTEN-dependent phenotype. 
 We have initiated a pilot project to confirm that the reduced body weight associated with 
PTEN overexpression is indicative of the effect of PTEN on cancer incidence and/or progression. 
To achieve this, we are utilizing three mouse cancer models: ApcMin-induced gastrointestinal 
cancer, 3-methylcholanthrene-induced sarcoma, and PYVT-induced metastatic mammary cancer. 
 
 
Figure 8. LOD Plot with Female Mice Data. QTL mapping produced a LOD plot 
showing areas of association on chromosome 3 and 12.  
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CHAPTER IV 
CONCLUSION 
 
We have identified genomic loci associated with body weight variation due to PTEN 
overexpression in male and female mice through QTL mapping. In male mice, nine genes 
including Mir466 are located within the QTL on chromosome 2.  In female mice, ten genes are 
located within the locus on chromosome 3 and eight genes including the transcriptional factor 
Gtf2a1 within the locus on chromosome 12.  
The next step of this project is to narrow down these gene lists to candidate PTEN 
modifier genes and to validate the extent of the modifier genes relationship with PTEN. 
Concurrently, three diverse mouse cancer models will be used to validate that this approach 
(using body weight as indicative of PTEN expression) plays a significant role in cancer initiation 
and/or progression. Understanding PTEN gene modifiers could provide insight into the causes, 
susceptibility and prevention of cancer. 
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